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, ⋅day -1 group compared with both baseline and control measurements (P < 0.0001). The expression of p-ERK in choroidal tissues was increased within 1 day of laser photocoagulation and remained elevated for 2 weeks. The expression of p-ERK was suppressed by sorafenib.
In conclusion, the current study showed that oral administration of the multikinase inhibitor sorafenib significantly suppressed the development of laser-induced CNV and caused regression of established CNV in mice.
Sorafenib interferes with multiple pro-angiogenic receptor tyrosine kinases, including VEGFR 2, PDGFR-β and Raf kinase, and thus holds promise for the treatment of CNV in clinical settings. 
Preventive treatment of laser-induced CNV
Mice were treated in accordance with the Association for Research in Vision and Ophthalmology guidelines for the use of animals in research. Choroidal neovascularization was induced by laser photocoagulation-induced rupture of Bruch's membrane, as described previously. 21 Briefly, 9-10-week-old female C57BL/6 mice were anesthetized with intraperitoneal zoletil (21 mg/kg, Zoletil 100; Virbac, Carros, France) and xylazine (7 mg/kg) and their pupils were dilated with 0.5% tropicamine and 0.5% phenylephrine (Mydrin-P, Santen, Osaka, Japan). To generate burns, three bursts of 532 nm diode laser photocoagulation (75-µm spot size, 0.1-second duration, 120 mW) were delivered to each retina using the slit-lamp delivery system of Visulas 532s
(Carl Zeiss, Jena, Germany), and using a handheld cover slip as a contact lens to view the posterior pole of the retina. Only burns that produced a bubble, indicating rupture of Bruch's membrane, were included in the study.
The mice were randomized into three groups: (1) respect to treatment group. 22 Mice used for the flat-mount technique were deeply anesthetized and perfused with 1 ml phosphate-buffered saline containing 50 mg/ml fluorescein-labeled dextran (2X10 6 average molecular weight; Sigma, St. Louis, MO), as previously described. 23 The mice were euthanized humanely, and eyes were removed and fixed for 1 hour in 10%
phosphate-buffered formalin. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. Radial cuts (four or five) were made from the edge to the equator and the eyecup was flat mounted in Aquamount with the sclera facing down. Flat mounts were examined by fluorescence microscopy using an Axioplan 2 microscope (Carl Zeiss, Jena, Germany), and images were digitized using an Axiocam camera and Axiovision version 4.5 image capture software. MetaMorph (version 4.6r5)
Professional Image Analysis software (Universal Imaging Corp.; Downingtown, PA) was used to measure the total area of CNV associated 1 1 with each burn, with the operator blinded with respect to treatment group.
Treatment of established CNV
To determine whether sorafenib was effective against established CNV, mice with Bruch's membrane ruptures at three locations in each eye were divided into four groups. In one group, mice were perfused 7 days after rupture of Bruch's membrane to measure the baseline size of CNV present at 7 days. The other three groups received 30 mg⋅kg On day 14, the mice were perfused with fluorescein-labeled dextran and the CNV area at each Bruch's membrane rupture site was measured on choroidal flat mounts.
Histologic procedures
A subset of mice (n=2 for each group) was sacrificed and the eyes were enucleated and processed for histopathology analysis. For histopathologic evaluation, the cornea was perforated by a needle to allow better penetration of the fixative and the intact eye was placed in 4% paraformaldehyde overnight and paraffin embedded using standard techniques. The eyes were sectioned into 5-µm-thick slices, stained with hematoxylin and eosin, and mounted on glass slides.
Western-blot analysis of the choroid and RPE layer
ERK phosphorylation was semiquantitatively evaluated by Western-blot analysis of the choroid and RPE layer from laser-treated and untreated C57BL/6 mice (n=3 mice for each group at each time point). Briefly, the vitreous and retina were removed, and the choroid and RPE layer were pooled 
Statistical analyses
Data were analyzed using a linear mixed model that accounts for possible correlations in measurements from the same mice. Dunnett's adjustment was made for multiple comparisons. The level of statistical significance was set at P < 0.05. 
III. RESULTS

1
Effect of sorafenib on established CNV
Fourteen days after laser treatment, mice that had received sorafenib 
. . . .
Histologic evaluation of laser burns
Histopathology analysis confirmed that CNV lesions in sorafenib-treated mice were smaller in diameter and had thinner centers compared with those in control animals. There was a discontinuity in Bruch's membrane in the area of each laser burn in both control and treatment groups. At the site of the laser spots, areas of fibrovascular tissue consisting of vessel lumen were observed.
Control mice treated with vehicle showed larger lesion areas consisting of fibrovascular tissue, RPE cells, and pigment clumps compared with mice that received sorafenib 1 day before laser injury ( Fig. 3) . 
Phosphorylated-ERK expression after laser photocoagulation and inhibition of CNV via p-ERK inhibition
Activation of the Raf/MEK/ERK kinase pathway in endothelial cells is necessary for angiogenesis. This signaling pathway also acts downstream of both VEGF and PDGF, so we investigated whether sorafenib treatment inhibited ERK phosphorylation in our CNV model. At days 1, 7 and 14 after laser injury, the expression level of p-ERK relative to that of total ERK increased compared with baseline levels. In laser-treated mice receiving sorafenib, the relative expression of p-ERK was reduced at all time points (Fig. 4) . 
IV. DISCUSSION
The laser-induced CNV model is widely used for the study but does not completely mimic naturally occurring CNV in age-related macular degeneration. 24 Nonetheless, the essential process such as the break-up of the basement membrane, the migration and proliferation of vascular endothelial cells, and tubular formation is similar, which validates the use of the laserphotocoagulation-induced model for evaluating the effect of a drug on CNV. 24 In this study, we showed that oral administration of sorafenib markedly inhibited CNV in a dose-dependent manner. Sorafenib treatment that began prior to laser-induced coagulation suppressed the development of CNV, and when administered after the establishment of neovascularization (7 days after Bruch's membrane rupture) caused CNV regression. Choroidal flat mounts demonstrated a significant reduction in CNV areas after sorafenib treatment.
Western-blot analyses of RPE/choroid layer revealed increased expression of p-ERK in RPE/choroid tissues, which was evident 1 day after Bruch's membrane rupture and was maintained through 2 weeks. The expression of p-ERK was suppressed by orally administered sorafenib at every time point.
Sorafenib is an oral multikinase inhibitor that inhibits VEGFR2, PDGFR-β and the serine threonine kinase Raf, which acts through the Raf/MEK/ERK kinase signaling pathway. 25 26 In addition to direct antitumor activity, sorafenib has been shown to possess anti-angiogenic properties. Recent reports have demonstrated that the anti-angiogenic effect of sorafenib might be a primary consequence of therapy and not a secondary effect owing to tumor cell loss and reduced production of angiogenic factors. 27 28 Recent case reports have also suggested possible therapeutic benefits of sorafenib in the treatment of exudative age-related macular degeneration. However, in these reports, sorafenib was administered either after or in conjunction with intravitreal injection of anti-VEGF drugs; thus, the direct therapeutic effect of sorafenib in CNV could not be proven. 29 30 Although targeting VEGF has recently been validated in clinical trials as an effective therapy for diseases associated with pathologic angiogenesis [31] [32] [33] , several other growth factor pathways have been shown to be involved in the process of pathologic angiogenesis, 34 35 and there is evidence that anti-VEGF therapy alone may not be sufficient to cause vessel regression in advanced 
